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Abstract
KDM5B (lysine[K]-specific demethylase 5B) is frequently upregulated in various human cancers 
including prostate cancer (PCa). KDM5B controls H3K4me3/2 levels and regulates gene 
transcription and cell differentiation, yet the contributions of KDM5B to PCa tumorigenesis 
remains unknown. In this study, we investigated the functional role of KDM5B in epigenetic 
dysregulation and PCa progression in cultured cells and in mouse models of prostate epithelium-
specific mutant Pten/Kdm5b. Kdm5b deficiency resulted in a significant delay in the onset of PCa 
in Pten-null mice, while Kdm5b loss alone caused no morphological abnormalities in mouse 
prostates. At 6 months of age, the prostate weight of Pten/Kdm5b mice was reduced by up to 70% 
compared to that of Pten mice. Pathological analysis revealed Pten/Kdm5b mice displayed mild 
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morphological changes with hyperplasia in prostates, whereas age-matched Pten littermates 
developed high grade-prostatic intraepithelial neoplasia (HG-PIN) and PCa. Mechanistically, 
KDM5B governed phosphatidylinositol 3-kinase (PI3K)/AKT signaling in PCa in vitro and in 
vivo. KDM5B directly bound the PIK3CA promoter and KDM5B knockout resulted in a 
significant reduction of P110α and PIP3 levels and subsequent decrease in proliferation of human 
PCa cells. Conversely, KDM5B overexpression resulted in increased PI3K/AKT signaling. Loss of 
Kdm5b abrogated the hyperactivation of AKT signaling by decreasing P110α/P85 levels in Pten/
Kdm5b mice. Taken together, our findings reveal that KDM5B acts as a key regulator of 
PI3K/AKT signaling; they also support the concept that targeting KDM5B is a novel and effective 
therapeutic strategy against PCa.
Introduction
Prostate cancer (PCa) is the second leading cause of cancer-related deaths in American men 
(1). The initiation and progression of PCa are driven by dysregulation of multiple oncogenic 
pathways secondary to genetic and epigenetic alterations of oncogenes and tumor 
suppressors. PTEN (Phosphatase and tensin homolog) is a tumor suppressor gene that is 
frequently deleted and/or mutated in various human cancers including PCa (2–6). Complete 
loss of Pten in the mouse results in invasive adenocarcinoma (7,8). PTEN acts as a 
phosphatase to dephosphorylate phosphatidylinositol 3, 4, 5-trisphosphate (PIP3) to 
phosphatidylinositol 4, 5-bisphosphate (PIP2). The ratio of PIP3/PIP2 in cells is tightly 
balanced by the enzymatic activities of PTEN phosphatase and phosphoinositide 3-kinases 
(PI3K). Loss of PTEN leads to the accumulation of PIP3 at the cell membrane and AKT 
activation, resulting in dysregulation of many cancer-related signaling pathways (9–12). 
Conversely, loss of PI3K such as P110α and P110β directly impaired AKT signaling to 
decrease cell proliferation and tumor growth (13,14). The essential role of the PI3K/AKT 
signaling pathways in PCa progression has long been recognized, but the targeting efficacy 
in PCa patients is still a challenge.
Dysregulation of the trimethylation of lysine 4 on histone H3 (H3K4me3) gene is frequently 
observed in advanced PCa and castration resistant PCa (15–17). Histone methylation is a 
reversible process that is tightly controlled by histone methyltransferases and demethylases 
to regulate biological functions in cells. Lysine-specific demethylase 5B (KDM5B, also 
called JARID1B or PLU1) is a JmjC domain-containing enzyme that removes methyl groups 
from tri- or di-methylated H3K4 (H3K4me3/2) to produce monomethylated H3K4 
(H3K4me1) (18). KDM5B is involved in chromatin remodeling to regulate a variety of 
biological functions including gene expression, genome stability, cell cycle, senescence, and 
metastasis (19–23). We and others showed that some Kdm5b germline knockout (KO) mice 
are viable but experience delayed development (24,25). Increased expression of KDM5B 
leads to drug resistance in some cancers such as melanoma (26,27). KDM5B upregulation is 
frequently found in advanced PCa, implicating its potential oncogenic role in PCa (28,29). 
However, it is still poorly understood how mechanistically KDM5B contributes to PCa 
progression.
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We recently reported that KDM5B is noticeably increased in prostate tumors of Pten/Trp53 
mutant mice (21). In this study, we demonstrated that KDM5B loss blocked PCa progression 
in Pten-null mice. More importantly, we discovered that KDM5B deficiency abolished the 
hyper-activation of PI3K/AKT signaling pathway in cultured cells and in mouse prostates. 
Mechanistically, KDM5B activates PI3K by increasing transcription and protein stability of 
P110α subunit in PCa cells. Thus, our findings provide novel insights into the underlying 
molecular mechanism by which KDM5B contributes to PCa progression, and offer a 
rationale to design small molecular inhibitors targeting the KDM5B and PI3K/AKT 
pathways.
Materials and Methods
Mutant mice and tumor analysis
PtenLoxP/LoxP, Kdm5bLoxP/LoxP, and PB-Cre4 mutant mice were generated and maintained 
as previously described (30,31). Mouse embryonic stem cells (EPD0027_1_F07, 
EPD0027_1_F09, EPD0027_1_H07, and EPD0027_1_G08) targeting Kdm5b in C57BL/6N 
background were obtained from the European Conditional Mouse Mutagenesis Program 
(EUCOMM). In these embryonic stem cells, exon 6 of Kdm5b was flanked by a FRT-lacZ-
neo-FRT-loxP cassette and a loxP site. After injection into C57BL/6 blastocysts, G08 line 
was selected to cross with a flippase expressing strain to obtain Kdm5bLoxP mice. 
PtenLoxP/+; PB-Cre4 male mice were crossed with Kdm5bLoxP/LoxP female mice to obtain 
the prostate-specific Pten/Kdm5b double mutants (PtenLoxP/LoxP; Kdm5bLoxP/LoxP; PB-
Cre4, referred to as Ptenpc–/–; Kdm5bpc–/–). All experimental animals were maintained in a 
mixed genetic background of C57BL/6J x 129/Sv x FVB. Animal experiments were 
performed in accordance with IACUC-approved protocols at Meharry Medical College and 
Yale University, respectively.
All genotypes of mice were verified by performing polymerase chain reaction (PCR) with 
DNA extracted from mouse tails according to the protocol previously described (30,31). 
PCR primers for genotyping were listed in Supplementary Table S1. PCR programs were 
run as 95°C for 2 min, then 95°C 30s, 57°C 1 min, 72°C 1 min for 30 cycles, with a final 
elongation at 72°C for 5 min. The expected sizes of PCR products designate the 349bp- 
Kdm5bwt, 516bp- Kdm5bLoxP, and 424bp- Kdm5bnull, respectively. After euthanasia, the 
prostate tissues or tumors of mice were procured. Tissues were fixed in 10% neutral-
buffered formalin (Sigma), washed, and preserved in 70% ethanol at 4°C. Haemotoxylin and 
Eosin (H&E) staining and immunohistochemistry (IHC) staining were performed by 
HistoWiz (Brooklyn, NY, USA). Antibodies used for IHC were rabbit anti pAKT Ser473 
(D9E) (Cell Signaling) and rabbit anti Ki67 (Abcam).
Mouse embryonic fibroblasts (MEFs)
MEFs were prepared from individual embryos of various genotypes in mice at E13.5-day 
according to the procedure previously described (30,32). Phoenix-eco cells cultured on Poly-
D-Lysine-Coated dishes were transfected with pMSCV-PIG-Cre or empty vector plasmids 
using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. MEFs at 
passage 2 were infected with fresh retroviral supernatant containing 4μg/ml polybrene 
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(Calbiochem). After selection with 3 μg/ml puromycin, MEFs at passage 5 were used for 
growth curve, western blot, and immunofluorescence (IF) analysis. To evaluate cell 
proliferation, MEFs were plated at 2×104 cells per well in a 24-well plate in triplicate, and 
cell proliferation was determined at 0, 2, 4, and 6 days by OD at 595nm with 0.1% crystal 
violet staining. To determine the activity of senescence, MEFs were plated at 1×104 cells per 
well of a 6-well plate in triplicate, and senescence-associated β-galactosidase (SA-β-gal) 
was detected after 4 days with the senescence detection kit (Calbiochem), photographed and 
quantified.
KDM5B knockout (KO) cells with CRISPR/Cas9
Three different single-guide RNA (sgRNA) sequences against KDM5B (sgRNA1: 5’ 
TCGAAGACCGGGCACTCGGG 3’, sgRNA2: 5’ GGACTTATTTCAGCTTAATA 3’, 
sgRNA3: 5’ CCTCCAATTCATTCAGTCTC 3’) were purchased from GenScript. 
pLentiCRISPR v2 plasmids containing KDM5B-sgRNA sequences, along with lentiviral 
packaging vectors PsPax2 and envelope plasmid pMD2.g, were transfected into HEK-293T 
cells using Lipofectamine 2000 (Invitrogen). pLentiCRISPR v2 empty vector was used as 
the control. Lentiviral supernatants were collected and filtered. PCa cells were infected with 
fresh viral supernatants, and then selected with 2 μg/ml of puromycin for 7 days. The 
resultant colonies were expanded and validated by western blot and sequencing analyses for 
KDM5B.
Cell culture, immunofluorescence (IF), and growth factor stimulation
LNCaP, C4–2B and PC3 human PCa cells were purchased from ATCC. LNCaP and C4–2B 
cells were grown in RPMI 1640 medium with 10% FBS and 1% Pen/Strep in an incubator 
with 5% CO2 at 37°C, while PC3 cells were maintained in DMEM complemented with 10% 
FBS and 1% Pen/Strep with 5% CO2 at 37°C. Proliferation and transfection assays were 
performed as previously described (30,32). Expression of target genes was determined 48–
72 hours post-transfection using real-time qPCR or western blot (33). For IF staining, cells 
fixed with methanol were incubated with rabbit anti-PIP3 (1: 250, Echelon Biosciences). 
After incubation of DAPI and secondary antibody, images were recorded (33). For growth 
factor stimulation, cells were starved, treated with IGF-1 (20ng/ml) and collected for 
western blot at 0, 5, 15, 30, 60 and 90 minutes after stimulation.
High throughput RNA sequencing
Total RNA was extracted from LNCaP KDM5B-KO and control cells using the RNeasy 
Mini Kit (Qiagen). cDNA library preparation and RNA-seq were performed in the 
VANTAGE core at Vanderbilt University. RNA-Seq reads were aligned to the hg19 genome 
using STAR [PMID: 23104886] and quantified by feature Counts [PMID: 24227677]. 
Differential analysis was performed by DESeq2 [PMID: 25516281], which estimated the 
log2 fold changes, Wald test p-values, and adjusted p-value (FDR) by the Benjamini-
Hochberg procedure. Paired-End (PE) sequencing was performed on all samples. Raw reads 
were de-multiplexed using a bcl2fastq conversion software v1.8.3 (Illumina, Inc.) with 
default settings.
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Real-time reverse transcription PCR and reporter assays
Real-time reverse transcription PCR (qRT-PCR) was performed using forward and reverse 
primers (Supplementary Table S2) as previously described (33). For PIK3CA promoter 
reporter assay, cells were transfected with 200 ng empty pLightSwitch_Prom reporter vector, 
50 ng, 100 ng or 200 ng of PIK3CA-promoter-Luc reporter plasmids (Switchgear Genomics, 
S706543). For KDM5B restoration, KDM5B-KO cells were co-transfected with pEV-Flag-
KDM5B plasmid (0~150ng) and 50 ng PIK3CA-promoter-Luc reporter. At 24 hours post-
transfection, cell lysates from each well were prepared in 100 μl of assay solution 
(Switchgear Genomics). 20 μl of lysates were kept to determine protein concentration, and 
the remaining lysates were used to measure the luciferase activities according to 
manufacturer’s instructions. Luciferase activities were normalized with the protein 
concentration.
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were performed as previously described (24). Briefly, LNCaP KDM5B-
KO and control cells were crosslinked with 1% formaldehyde and then quenched by 0.125M 
glycine. Cell pellets were lysed in a buffer (20 mM Tris•HCl, pH8.0, 2 mM EDTA, 0.5 mM 
EGTA, 0.5% SDS, 0.5 mM PMSF) and followed with a brief sonication. After 
centrifugation, chromatin was pre-cleared with protein A/G beads. For each ChIP reaction, 2 
μg anti-H3K4me3 antibody (ab8580, Abcam), 3 μg anti-KDM5B antibody (NB100–97821, 
Novus) or IgG were added and incubated overnight at 4°C. Next morning, 200 μl pre-
washed protein A/G beads were added to each IP and rotated at 4°C for 3 hrs. Beads were 
pelleted, washed, and eluted 2x by elution buffer. DNA was extracted for qPCR analyses 
(Supplementary Table S3) (24).
Western blot and half-life determination of P110α and P85 proteins
Cell lysates were prepared in RIPA buffer (1×PBS, pH7.4, 1% Nonidet P40/Triton X-100, 
0.5% sodium deoxycholate, 2mM EDTA, with or without 0.1% SDS) with protease inhibitor 
cocktail (Roche) followed with a brief sonication. For mouse prostate analysis, protein 
extracts were prepared as previously described (30). For the protein stability of P110α and 
P85 proteins, KDM5B-KO and control cells were incubated with 100 μg/ml of 
cycloheximide (CHX, Sigma), and cell lysates were collected at indicated time points for 
western blot analysis (32). Antibodies used were: anti-H3K4me3 (1: 5,000, Cell Signaling, 
9727), anti-H3 (1: 5,000, Abcam, Ab1791), anti-KDM5B (1: 2,000, Novus Biologicals, 
NBP1–84352), anti-KDM5A(1: 1,000, Cell Signaling, 3876), anti-KDM5C(1: 1,000, Cell 
Signaling, 5361), anti-β-actin (1: 10,000, Sigma, AC-74), anti-PTEN (1: 1,000, Cell 
Signaling, 9559), anti-P110α (1: 1,000, Cell Signaling, 4255), anti-P85 (1: 1,000, Cell 
Signaling, 4292), anti-AKT (1: 1,000, Cell Signaling, 9272), anti-pAKT Ser473 (1: 1,000, 
Cell Signaling, 4051), anti-pAKT Thr308 (1: 1,000, Cell Signaling, 4056), anti-SHIP1 (1: 
1,000, Cell Signaling, 2728), and anti-β-Galactosidase (1: 1,000, Cell Signaling, 27198).
Statistical analysis
Statistics analysis was performed using two-tail Student’s t-test. The values of P < 0.05 were 
considered statistically significant.
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Kdm5b inactivation suppresses the initiation and progression of prostate cancer in Pten-
null mutant mice
To study the effects of KDM5B loss on the initiation and progression of PCa in vivo, we 
took advantage of the striking disease phenotype of PCa in Pten mouse model and generated 
prostate epithelium-specific Pten/Kdm5b double null (Ptenpc–/–; Kdm5bpc–/–) mice (Fig. 1A 
and Supplementary Fig. S1A–C). In agreement with our previous report (30), the 
enlargement of anterior prostate (AP) lobes was noticeable in Pten conditional null 
(Ptenpc–/–) mice at 6 months of age (Fig. 1A), and the average of AP weight was 4 times 
greater than that of the age-matched wild type (Wt) cohort (Fig. 1B). Consistent with the 
idea that KDM5B is required for PCa, the size and average AP weight of Ptenpc–/–; 
Kdm5bpc–/– mice at 6 months of age were significantly lower than that of age-matched 
Ptenpc–/– mice, and similar to that of age-matched Wt mice (Fig. 1A and B). Furthermore, 
pathological analysis revealed that Ptenpc–/– mice developed high-grade PIN lesions and 
adenocarcinoma in all three lobes of the prostate, namely AP (Fig. 1C), dorsal/lateral (DLP), 
and ventral prostate (VP) (Supplementary Fig. S2A). The high-grade PIN lesion displayed a 
highly dysplastic luminal epithelium and the presence of nuclear atypia. In contrast, 
Ptenpc–/–; Kdm5bpc–/– mice showed only mild hyperplasia or low-grade PIN lesion in some 
prostate glands (~about 40%) (Fig. 1C and D, Supplementary Fig. S2A). Kdm5b deficiency 
alone did not cause morphological changes to the prostates (Fig. 1C, Supplementary Fig. 
S2A), as mice displayed the monolayer of luminal epithelial cells with normal recurrent 
mucosal folds projecting into the prostate gland. These data support that Kdm5b deficiency 
resulted in suppression of the initiation and progression of PCa in vivo.
Kdm5b deficiency abrogates AKT signaling through reduction of PI3K in vivo
PTEN functions as a bona fide antagonist of the phosphatidylinositol 3-kinase/protein kinase 
B (PI3K/AKT) pathway, therefore loss of PTEN results in a hyper-activation of AKT 
signaling. Our IHC staining results showed a striking increase of phosphorylated-AKT 
(pAKT-S473) at the membrane in prostates of Ptenpc–/– mice as compared to Wt mice (Fig. 
2A). Interestingly, pAKT-S473 levels in prostates of Ptenpc–/–; Kdm5bpc–/– mice were 
significantly decreased as compared with that of Ptenpc–/– mice (P<0.05, Fig. 2A–C and 
Supplementary Fig. S2B). In addition, the proliferation rates as measured by Ki67 staining 
were also significantly decreased in Ptenpc–/–; Kdm5bpc–/– mice as compared to Ptenpc–/– 
mice (P< 0.005, Fig. 2A and B, Supplementary Fig. S2B). These results suggest that Kdm5b 
governs the hyper-activation of the PI3K/AKT signaling pathway in Pten-null mice. 
Surprisingly, the rate of apoptosis as measured by TUNEL levels decreased in Ptenpc–/–; 
Kdm5bpc–/– mice as compared to Ptenpc–/– mice (P< 0.005, Fig. 2A–B, Supplementary Fig. 
S2B). Furthermore, consistent with the findings in IHC, western blotting analysis confirmed 
that the levels of pAKT (Ser473 and Thr308) were significantly decreased in Ptenpc–/–; 
Kdm5bpc–/– mice compared to Ptenpc–/– mice (P<0.005 or P< 0.05, Fig. 2C–D). The levels 
of pAKT in Kdm5bpc–/– mice were lower than that in Wt mice (Fig. 2C). The levels of 
Kdm5b, along with pAKT, were significantly increased in Ptenpc–/– mice as compared to 
that of Wt mice (Fig. 2C), in consonance with our previous report (21). As KDM5B 
inactivation did not trigger the induction of apoptosis pathway, we examined the status of 
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senescence program in Ptenpc–/–; Kdm5bpc–/– mice. Western blotting analysis revealed the 
levels of senescence-associated β-galactosidase (SA-β-Gal) were upregulated in prostates of 
Ptenpc–/–; Kdm5bpc–/– mice as compared to that of Ptenpc–/– mice (Supplementary Fig. S2C 
and D), indicating that Kdm5b ablation induces senescence. These results strongly support 
the idea that KDM5B is essential for the hyper-activation of the PI3K/AKT signaling 
pathway, and that Kdm5b deficiency suppresses PCa progression in mice by blocking AKT 
hyper-activation with induction of senescence.
AKT activation is tightly regulated by both PI3K and PTEN. P110 protein acts as the 
catalytic subunit of the PI3K complex, while P85 is the regulatory subunit. Therefore, we 
investigated the impact of Kdm5b loss on the levels of P110α and P85 proteins. 
Interestingly, western blotting analysis revealed that the protein levels of P110α in Ptenpc–/–; 
Kdm5bpc–/– mice were significantly decreased (by 60%) as compared to that in Ptenpc–/– 
mice (P< 0.005, Fig. 2C and D), while the protein levels of P85 decreased by about 15%. 
These findings indicated that Kdm5b plays an essential role in the regulation of PI3K levels 
as well as in the activation of AKT signaling in vivo.
Kdm5b is essential for cell proliferation and the activation of the PI3K-PIP3-AKT axis in 
vitro
To further delineate the biological role of Kdm5b inactivation in vitro, we prepared mouse 
embryonic fibroblasts (MEFs) of Pten null (PtenΔ/Δ) and Pten/Kdm5b double null (PtenΔ/Δ; 
Kdm5bΔ/Δ) from mice by following the strategy reported previously (30,32). Virus-mediated 
expression of Cre led to efficient recombination of loxP alleles as confirmed by PCR 
(Supplementary Fig. S3A). Interestingly, the proliferation rates of both PtenΔ/Δ; Kdm5bΔ/Δ 
and Kdm5b null (Kdm5bΔ/Δ) MEFs were significantly decreased as compared to Wt MEFs 
(Fig. 3A). The proliferation rate of PtenΔ/Δ MEFs was comparable to that of the Wt MEFs 
(Fig. 3A), in agreement with our previous report (30). Importantly, the proliferation rate of 
PtenΔ/Δ; Kdm5bΔ/Δ MEFs was significantly lower than that of PtenΔ/Δ MEFs (Fig. 3A), 
supporting the idea that Kdm5b plays a potentially oncogenic role in promoting cell 
proliferation. Moreover, western blotting analysis demonstrated that Pten inactivation 
resulted in an elevation of KDM5B protein in PtenΔ/Δ MEFs as compared to that in Wt 
MEFs (Fig. 3B), in line with the results in vivo (Fig. 2C). In addition, the levels of P110α, 
P85, and pAKT (Ser473 and Thr308) in PtenΔ/Δ; Kdm5bΔ/Δ MEFs were significantly 
decreased as compare to that of PtenΔ/Δ MEFs (P< 0.005 or P< 0.05, Fig. 3B and C). 
Meanwhile, Pten loss alone did not cause any changes of P110α and P85 levels (Fig. 3B).
Given that Kdm5b inactivation decreases the levels of P110α and P85, we wished to assess 
the changes of PIP3 levels in MEFs. PI3K catalyzes the phosphorylation of PIP2 to PIP3 at 
the membrane, while PTEN dephosphorylates PIP3 to PIP2. IF images revealed that PIP3 
predominantly accumulated at the membrane of PtenΔ/Δ MEFs (Fig. 3D and Supplementary 
Fig. S3B), with no signal detected in nucleus and cytosol (34–36). As shown, PIP3 levels in 
PtenΔ/Δ MEFs were much higher as compared to Wt MEFs (Fig. 3D). Most importantly, 
PIP3 levels of PtenΔ/Δ; Kdm5bΔ/Δ MEFs were significantly lower compared to that of 
PtenΔ/Δ MEFs (P<0.005, Fig. 3D and E). These results supported the idea that Kdm5b loss 
reduced levels of both PI3K and PIP3 to abrogate AKT signaling in vitro.
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Moreover, PtenΔ/Δ; Kdm5bΔ/Δ MEFs showed stronger positivities for SA-β-Gal than PtenΔ/Δ 
MEFs and Kdm5bΔ/Δ MEFs (Fig. 3F). The percentage positive for SA-β-Gal in PtenΔ/Δ; 
Kdm5bΔ/Δ MEFs was significantly higher than that in PtenΔ/Δ MEFs (P<0.05, Fig. 3G), 
which is consistent with western blotting results of SA-β-Gal (Fig. 3B and C). These results 
strongly support that Kdm5b ablation induces senescence in vitro.
KDM5B KO decreases the proliferation of PTEN-null human PCa cells through impairing 
the PI3K-PIP3-AKT axis
These findings from genetically-engineered mouse models in vivo and MEFs in vitro 
propelled us to investigate the impact of KDM5B loss on biological traits and molecular 
mechanisms in human PCa cells. We chose to use LNCaP, C4–2B, and PC3 human PCa cell 
lines, which are PTEN-null, pAKT-high and KDM5B-high. We first generated KDM5B-KO 
PCa cells using CRISPR/Cas9. In addition to sequencing analysis, our western blotting 
results confirmed that KDM5B-KO cells failed to express KDM5B protein without affecting 
the levels of KDM5A and KDM5C (Fig. 4A, Supplementary Fig. S4A–B). We then asked 
whether KDM5B-KO causes any decreases of PI3K (P110α/P85) and pAKT (Ser473/
Thr308). Indeed, P110α levels in all three KDM5B-KO human PCa cell lines decreased 
significantly (~50%) as compared to that in the parental control cells (Fig. 4A, 
Supplementary Fig. S5A–B, and Supplementary Fig. S6A–B). Meanwhile, P85 levels in 
KDM5B-KO cells decreased by about 30% (Fig. 4A, Supplementary Fig. S6A–B). Most 
importantly, the levels of pAKT (Ser473 and Thr308) in KDM5B-KO PCa cells decreased 
significantly as compared to that in the control cells (Fig. 4A, Supplementary Fig. S5A–B, 
and Supplementary Fig. S6A–B). Furthermore, KDM5B-KO led to a significant reduction of 
the proliferation of PCa cells as compared to the control cells (Fig. 4B, Supplementary Fig. 
S5B and S6B). Similarly, KDM5B-KO resulted in a significant reduction of PIP3 levels at 
the membrane of human PCa cells (P< 0.005, Fig. 4C and Supplementary Fig. S4B). Our 
results from multiple human PCa cell lines further confirmed that KDM5B plays a critical 
role in activation of the PI3K-PIP3-AKT signaling axis, in agreement with our data from 
mouse models and MEFs.
KDM5B induces P110α levels by increasing transcription and protein stability
We reasoned that KDM5B might directly induce the levels of PI3K (P110α/P85) at either 
the transcriptional or the post-transcriptional level. We performed RNA-Seq analysis in the 
LNCaP KDM5B-KO and the control cells, and the RNA-Seq peaks showed the suppressive 
impact of KDM5B-KO on the expression of IRS1, PIK3CA (encoding for P110α) and 
PIK3R1 (encoding for P85) (Fig. 4D). Furthermore, our qRT-PCR results showed that 
mRNA levels of PIK3CA gene in LNCaP KDM5B-KO cells decreased significantly as 
compared to that in the control cells (P<0.05, Fig. 4E), Surprisingly, the mRNA levels of 
PIK3R1 in LNCaP cells were not affected by KDM5B-KO (Fig. 4E). Therefore, we asked 
whether KDM5B-KO contributed to the protein stability of P110α and P85 in PCa cells. Our 
CHX chase experiments revealed that KDM5B ablation shortened the half-life of both 
P110α (7.2 vs 8.2 hr) and P85 (7.0 vs 10.5 hr) protein (Fig. 4F). These lines of biochemical 
evidence indicated that KDM5B loss differentially decreases PI3K (P110α/P85) in PCa cells 
at both the transcriptional and post-transcriptional levels.
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We hypothesized that KDM5B plays an integral role on the transcriptional initiation of 
PIK3CA gene through its promoter. To test this, we performed ChIP analysis and compared 
the levels of KDM5B and H3K4me3 at the PIK3CA promoter in LNCaP KDM5B-KO and 
the control cells (Fig. 5A). Since no KDM5B protein was expressed in the KDM5B-KO 
cells, the enrichment of KDM5B was comparable with the IgG-ChIP control. We detected a 
significant reduction of the binding at the PIK3CA promoter in KDM5B-KO cells as 
compared to that in control cells (Fig. 5B). Surprisingly, the enrichment of H3K4me3 at the 
PIK3CA promoter was either lower or unchanged in KDM5B-KO cells as compared to the 
control cells (Fig. 5C). H3K4me3 is commonly regarded as an activating mark for gene 
transcription; therefore the results provided one explanation why KDM5B-KO deceased the 
PIK3CA expression. We further performed a bioluminescent reporter assay in both LNCaP 
and C4–2B cells using the PIK3CA promoter-driven luciferase reporter (Fig. 5D). Our 
results revealed that the luciferase activities of PIK3CA promoter in both LNCaP KDM5B-
KO and C4–2B KDM5B-KO cells decreased significantly as compared to the control cells 
(P<0.005, Fig. 5D; P<0.05, Supplementary Fig. S7A). To confirm this transcriptional 
regulation, we restored KDM5B expression in KDM5B-KO PCa cells by co-transfecting 
Flag-KDM5B plasmids along with PIK3CA promoter luciferase reporter. Our results 
demonstrated that, in KDM5B-KO cells, the transcriptional activities of PIK3CA promoter 
were positively correlated with KDM5B expression in a dose dependent manner (Fig. 5E, 
Supplementary Fig. S7B).
Overexpression (OE) of KDM5B increased P110α levels to promote the hyperactivation of 
AKT signaling
Given that KDM5B-KO abrogates the PI3K/AKT signaling in the PTEN-Null context, we 
postulated that KDM5B-OE would enhance the PI3K/AKT signaling. We chose BHPrE1 
cells, a non-tumorigenic human prostate epithelial cell line expressing low levels of 
KDM5B, to assess the effects of KDM5B-OE on the PI3K/AKT signaling. After Flag-
KDM5B was ectopically expressed in BHPrE1 cells, qRT-PCR results showed that mRNA 
levels of PIK3CA were increased (~30%) as compared to that in control cells (P<0.05, 
Supplementary Fig. S7C). Remarkably, western blotting analysis revealed that levels of 
P110α protein were significantly increased and positively correlated with KDM5B elevation 
in a dose dependent manner (P<0.005, Fig. 6A and B). The levels of pAKT (Ser473/Thr308) 
were significantly increased upon KDM5B-OE (P<0.005, Fig. 6A and B). However, 
KDM5B-OE did not lead to an increase of P85 protein in BHPrE1 cells (Fig. 6A), consistent 
with the KDM5B-KO results. These data strongly support that KDM5B activates the 
PI3K/AKT signaling pathway in PCa cells.
Since KDM5B addback in LNCaP KDM5B-KO cells increased the transcriptional activities 
of PIK3CA (Fig. 5E), we examined the impact of KDM5B restoration on the protein levels 
of PI3K and pAKT. We transfected Flag-KDM5B plasmids into LNCaP KDM5B-KO cells 
and collected cell lysates at 48 hours post-transfection. Western blotting analysis 
demonstrated that the levels of P110α and pAKT (Ser473/Thr308) proteins were notably 
increased in KDM5B-KO cells upon KDM5B restoration, and the elevation of P110α and 
pAKT (Ser473/Thr308) proteins was positively correlated with KDM5B expression in a 
dose dependent fashion (P<0.05, Fig. 6C and D). However, KDM5B restoration only led to a 
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marginal increase of P85 protein in LNCaP KDM5B-KO cells (Fig. 6C and D), consistent 
with the results of KDM5B-OE in BHPrE1 cells (Fig. 6A).
KDM5B KO impairs the insulin signaling pathway in human PCa cells
P110α is the primary PI3K subunit responding to insulin signaling in liver and adipocytes 
(37,38). Our RNA-Seq analysis and qRT-PCR showed that mRNA levels of IRS1 in 
KDM5B-KO cells decreased about 50% as compared to the control cells (P<0.05, Fig. 4D 
and E). Therefore, we assessed the effects of KDM5B-KO on insulin signaling and 
subsequently the downstream PI3K/AKT pathway in PCa cells upon growth factor 
stimulation. To this end, PC3 KDM5B-KO and the control cells were subject to serum-
starvation and insulin-like growth factor-1 (IGF-1) stimulation (Fig. 6E). We found that 
KDM5B-KO cells showed a retarded elevation of P110α, P85, and pAKT levels as 
compared with the control cells upon IGF-1 treatment (Fig. 6E and F). The elevated levels of 
P110α at all time points were significantly restrained (up to 60%) in the KDM5B-KO cells 
as compared to that in the control cells (Fig. 6E and F). Our findings suggest that KDM5B is 
essential for the insulin signaling, and KDM5B-KO impaired the IGF responses in PCa 
cells.
Discussion
Aberrant elevation of KDM5B is often found in various human cancers including PCa 
(28,29); however, the function roles of KDM5B on the initiation and progression of PCa are 
poorly understood (29). Our studies provided valuable information on decoding the 
biological function of KDM5B in 2 ways: 1) Kdm5b deficiency significantly suppresses the 
progression of prostate tumorigenesis in Ptenpc–/– mice; and 2) KDM5B activates the 
PI3K/AKT signaling pathway in PCa cells through regulation of P110α and PIP3 levels. We 
employed both genetically-engineered mouse models and CRISPR/Cas9 technologies to 
elucidate the contributions and action mechanism of KDM5B on PCa progression. Our 
findings demonstrated for the first time that KDM5B acts as an oncogenic driver for PCa, 
and furthermore illuminated that KDM5B is essential for the hyper-activation of PI3K/AKT 
signaling pathways in PCa.
We previously demonstrated that KDM5B is noticeably increased in prostate tumors of Pten-
null mice in which AKT signaling is hyper-activated due to Pten inactivation (21). 
Meanwhile, a reduction of AKT signaling upon KDM5B knockdown was reported in gastric 
cancer cells and hepatocellular carcinoma (39,40). Nevertheless, the molecular contributions 
of KDM5B loss to the AKT signaling remain unclear. In this study, we discovered that 
KDM5B-KO abolished the PI3K/AKT signaling in mouse models, MEFs, and human PCa 
cells, in harmony with previous reports. Our results from both KDM5B-KO and KDM5B-
OE experiments revealed that KDM5B activates the AKT signaling through regulation of 
PI3K (P110α and P85) and PIP3 levels to promote PCa progression, providing novel 
mechanistic explanations on the KDM5B-AKT association in human cancers.
Interestingly, we found that KDM5B regulates the mRNA levels and the protein stability of 
P110α in PCa cells, adding novel insights into other mechanisms previously reported. For 
example, KDM5B-OE in hepatocellular carcinoma activated the AKT signaling through 
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downregulation of PTEN expression via PTEN-promoter (40). KDM5B-OE in human 
hypopharyngeal squamous cells activated the AKT signaling by decreasing INPP5D 
(encoding for SHIP1 protein) expression (41). We examined the contributions of SHIP1 
protein on the AKT signaling in both mouse prostates and human PCa cells. Our data 
revealed that the expression level of SHIP1 protein in mouse prostates is very low as 
compared to that in mouse spleen (Supplementary Fig. S8A). KDM5B-KO did not cause 
any visible changes of SHIP1 protein in PCa cells, as SHIP1 protein levels are also low in 
these cell lines. Moreover, our RNA-Seq analysis revealed that the numbers of reads 
(FPKM) for INPP5D gene are below 8 in LNCaP cells. Therefore, it is unlikely that SHIP1 
protein is involved in the regulation of the PI3K/AKT signaling in PCa, suggesting the 
diversities of SHIP1 signaling in tissues.
AKT signaling pathway plays an important role on regulation of epigenetic events including 
posttranscriptional histone modifications (42–44). Recent reports showed that AKT 
decreased H3K4me1/2 levels by phosphorylation and attenuation of lysine methyltransferase 
2D (KMT2D or MLL2/4) at S1331 (45,46), but also increased H3K4me3 levels by 
restraining KDM5A protein in cytosol in breast cancer (47). AKT can increase KDM5B 
levels and cancer stem cell populations in oral cancer cells, highlighting an impact of the 
PI3K/AKT pathway on KDM5B expression in cancers (48). However, our data showed that 
either PI3K inhibition by LY294002 or AKT inhibition by MK-2206 did not result in any 
changes of KDM5B/H3K4me3 levels in LNCaP and C4–2B PCa cells (Supplementary Fig. 
S8B–E). Given the impact of KDM5B loss on suppression of PCa growth, the role of 
KDM5B/H3K4me3 on gene expression and malignancy in castration resistant PCa deserves 
further investigation.
KDM5B has mainly been studied as a transcriptional repressor. However, several studies 
reported that KDM5B could be a transcription activator, likely in a demethylase-independent 
manner. For example, one study reported that KDM5B is a transcription activator of self-
renewal-associated genes in embryonic stem cells (ESCs), and KDM5B depletion decreased 
expression of genes associated with mitosis and nuclear metabolism (49). We have 
previously shown that KDM5B recruits GATA3 to promote FOXA1 expression in mammary 
epithelial cells (24). Our study showed that H3K4me3 levels are increased in PCa cells upon 
KDM5B-KO; but interestingly, the H3K4me3-ChIP data clearly revealed that the enrichment 
of H3K4me3 at the promoter of PIK3CA gene was lower or unchanged in KDM5B-KO cells 
as compared to that in the control cells. The lower levels of H3K4me3 are correlated with 
the decreased expression of PIK3CA. These results suggest that KDM5B regulates PIK3CA 
in a demethylase activity-independent manner, at least in PCa.
Dysregulation of the PTEN-PI3K-AKT signaling pathways is essential for PCa progression, 
but the efficacy of targeting AKT in PCa patients is still a challenge. However, most AKT 
inhibitors display a rather limited clinical activity as single agents. Our study suggests some 
options on the combinatorial treatments for better therapeutic perspective of PI3K or AKT 
inhibitors. Importantly, the genetic evidence of this study highlights that KDM5B-deficient 
PCa cells decrease proliferation and are more vulnerable to another cancer inhibitor. It is 
predicted that a combined inhibition of KDM5B and AR (or PARP) should be new avenues 
of blocking malignant transformation, prostate tumorigenesis and distant metastasis of PCa. 
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Moreover, KDM5B degraders instead of catalytic site inhibitors would be also a new avenue 
of PCa intervention. Overall, our findings support the idea that targeting KDM5B can be a 
novel and effective therapeutic strategy of controlling PCa.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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This study demonstrates that levels of histone modification enzyme KDM5B determine 
hyperactivation of PI3K/AKT signaling in prostate cancer and that targeting KDM5B 
could be a novel strategy against prostate cancer.
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Figure 1. Kdm5b inactivation suppresses prostate tumorigenesis of Pten-null mice in vivo.
(A)Top panel, a schematic showing the strategy of generating Pten/Kdm5b mutant mice. 
Bottom panel, the actual sizes of representative biopsies of anterior prostates (AP) from Wt, 
Ptenpc–/–, Kdm5bpc–/–, and Ptenpc–/–; Kdm5bpc–/– mice at 6 months of age. (B) 
Quantification of AP weights from indicated genotypes of mice at 6 months of age. The 
averages of AP weight and numbers of mice for each cohort are indicated. (C) H&E staining 
of AP from indicated genotypes of mice at 6 months of age (Magnification: 4X and 20X). 
(D) Comparison of the onset of PIN in prostate glands between Ptenpc–/– and Ptenpc–/–; 
Kdm5bpc–/– mice. Error bars represent means ± SD (3 mice/group).
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Figure 2. Kdm5b deficiency abrogates AKT signaling through reducing PI3K levels in vivo in 
mouse prostates.
(A) Immunohistochemical (IHC) staining for pAKT(S473), Ki67 and TUNEL in prostate 
tissues from indicated genotypes of mice at 6 months of age (Magnification: 20X). (B) 
Quantification of the prostate cells positive for pAKT(S473), Ki67 and TUNEL in (A). Error 
bars represent means ± SD from 3 mice for each group. (C) Western blotting analysis of 
protein levels of Pten, Kdm5b, pAKT, P110α, and P85 in prostate tissues of mice with 
indicated genotypes. Two mouse prostate samples for each genotype. (D) Quantification of 
protein levels for pAKT, P110α, and P85 between Pten/Kdm5b double null and Pten null 
mice. Error bars represent means ± SD of triplicates.
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Figure 3. Kdm5b is essential for the hyperactivation of the PI3K/AKT signaling pathway in 
MEFs.
(A) Effects of Kdm5b inactivation on the cell proliferation of MEFs. Error bars represent 
means ± SD of triplicates. (B) Western blotting analysis of protein levels of Pten, Kdm5b, 
pAKT, P110α, P85, and β-galactosidase in MEFs with indicated genotypes. (C) 
Quantification of protein levels for pAKT, P110α, P85, and β-galactosidase between Pten/
Kdm5b double null and Pten null MEFs. Error bars represent means ±SD of triplicates. (D) 
Immunofluorescence (IF) images showing the levels and membrane localization of PIP3 in 
MEFs with indicated genotypes. (E) Quantification of fluorescence intensities for PIP3 
levels in MEFs. Error bars represent means ± SD (20 cells/ group). (F) Images showing the 
β-galactosidase staining in senescent MEFs. (G) Quantification of the MEFs positive for β-
galactosidase. Error bars represent means ± SD (30 cells/ group).
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Figure 4. KDM5B knockout abrogates PI3K/AKT signaling in human prostate cancer cells.
(A) Left panel, western blotting analysis showing the protein levels of KDM5B, pAKT, 
P110α, and P85 in LNCaP KDM5B-KO and the parental control human PCa cells. Right 
panel, quantification analysis of pAKT, P110α, and P85 in LNCaP KDM5B-KO and the 
control cells. (B) A comparison of the cell proliferation between LNCaP KDM5B-KO and 
the control cells. (C) Immunofluorescence (IF) images and analysis of PIP3 in LNCaP 
KDM5B-KO cells. Left panel, IF images showing the levels and membrane localization of 
PIP3 in LNCaP KDM5B-KO cells and the control cells. Right panel, quantification of the 
fluorescence intensities of PIP3 in LNCaP KDM5B-KO and the control cells. Error bars 
represent means ± SD (20 cells/group). (D) RNA-Seq peaks showing the changes of 
KDM5B, IRS1, PIK3CA, and PIK3R1 expression between LNCaP KDM5B-KO and the 
control cells. (E) Quantitative RT-PCR analysis to show the relative mRNA levels of IRS1, 
PIK3CA, and PIK3R1 in LNCaP KDM5B-KO cells. (F) Top panel, western blotting 
analysis showing the protein levels of KDM5B, P110α and P85 in LNCaP KDM5B-KO and 
the control cells at indicated time points in CHX chase experiments. Bottom panel, 
quantification of protein remaining for P110α and P85 at indicated time points in KDM5B-
KO and the control cells.
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Figure 5. KDM5B controls the PIK3CA expression in human prostate cancer cells.
(A) A schematic showing the positions of 5 amplicons relative to the PIK3CA transcription 
start site (TSS). (B) ChIP analysis of KDM5B levels at the indicated regions near PIK3CA 
TSS in LNCaP KDM5B-KO and the parental control cells. (C) ChIP analysis of H3K4me3 
levels at the indicated regions near PIK3CA TSS in LNCaP KDM5B-KO and the control 
cells. (D) Top panel, a schematic showing that KDM5B regulates the transcription of 
PIK3CA through affecting promoter activities. Bottom panel, comparisons of luciferase 
activities of the PIK3CA promoter between LNCaP KDM5B-KO cells and the parental 
control cells. (E) Luciferase activities showing the effects of KDM5B restoration on the 
PIK3CA promoter activities in LNCaP KDM5B-KO cells.
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Figure 6. The PI3K/AKT signaling and IGF responses are regulated by KDM5B in human 
prostate cancer cells.
(A) Western blotting analysis showing the increased levels of P110α and pAKT (Ser473/
Thr308) in BHPrE1 cells upon KDM5B overexpression. (B) Quantification of the levels for 
P110α and pAKT in BHPrE1 cells from (A). (C) Western blotting analysis showing that the 
effects of KDM5B restoration on the levels of P110α, P85 and pAKT (Ser473/Thr308) in 
LNCaP KDM5B-KO cells. (D) Quantification of the protein levels for pAKT, P110α and 
P85 in LNCaP KDM5B-KO cells from (C). (E) Western blotting analysis showing the 
differential responses between PC3 KDM5B-KO and the parental control cells to IGF-1 
stimulation. (F) Quantification of protein levels for pAKT (Ser473/Thr308), P110α, and P85 
in (E). Error bars represent means ±SD of triplicates.
Li et al. Page 21
Cancer Res. Author manuscript; available in PMC 2021 May 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
